Please assess the completion status of the following clinical trial:

Trial Title: Effects of Dehydroepiandrosterone Supplementation on Cumulus Cells Gene Expression Under Controlled Ovarian Hyper-stimulation in Patients With Diminished Ovarian Reserve

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* DOR: antral follicle count (AFC) less than 5, AntiMullerian hormone (AMH) less than 1.0 ng/ml, and previous total retrieved oocyte less than 5.~* Normal Control: antral follicle count (AFC) equal to or more than 5, AntiMullerian hormone (AMH) equal to or more than 1.0 ng/ml, and previous total retrieved oocyte equal to or more than 5.~Patient provided signed informed consent.~Exclusion Criteria:~* Patient who has the allergic history or contraindication to DHEAS usage.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- DHEAS in DOR Group (Type: ACTIVE_COMPARATOR): Additional usage of DHEAS supplement in patients with DOR under ovarian hyper-stimulation protocol.
- Normal Control (Type: ACTIVE_COMPARATOR): Patients under ovarian hyper-stimulation protocol. No DHEAS supplement.
- Shame DOR Group (Type: ACTIVE_COMPARATOR): Patients with DOR under ovarian hyper-stimulation protocol. No DHEAS supplement.

Based on this trial design, predict the completion outcome and termination type (if applicable).